The global market for Specimen Collection Cards was estimated at US$450.8 Million in 2024 and is projected to reach US$559.7 Million by 2030, growing at a CAGR of 3.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Specimen Collection Cards market.
Global Specimen Collection Cards Market - Key Trends & Drivers Summarized
Why Are Specimen Collection Cards Gaining Critical Importance in Modern Diagnostics?
Specimen collection cards have become an essential tool in modern medical diagnostics, public health surveillance, and biomedical research, primarily due to their ability to simplify biological sample collection, preservation, and transportation. Designed to collect and store dried blood spots (DBS), saliva, buccal cells, or other biological fluids on treated paper or membranes, these cards offer a minimally invasive, low-cost, and logistically efficient solution for sample acquisition - especially in remote or resource-limited settings. With global healthcare systems increasingly focused on decentralization and preventive care, the use of specimen collection cards is expanding across applications such as newborn screening, infectious disease monitoring, genetic testing, forensic analysis, and even personalized medicine. Their stability at ambient temperatures eliminates the need for cold-chain logistics, reducing both complexity and cost. Moreover, the pandemic-era emphasis on mail-in testing and at-home sample collection has brought specimen collection cards into the spotlight as part of scalable diagnostics and bio-surveillance strategies. Whether in clinical trials, field-based epidemiology, or telehealth settings, these cards are supporting the global shift toward more accessible and resilient health monitoring frameworks.How Are Innovations in Card Design and Sample Stability Enhancing Market Adoption?
Technological advancements in filter paper treatment, analyte stabilization, and multi-sample integration are transforming the capabilities of specimen collection cards. Manufacturers are now producing cards with enhanced chemical coatings that preserve nucleic acids (DNA, RNA) and proteins more effectively, extending shelf life and improving the integrity of analytes under varied environmental conditions. Some cards are embedded with indicator dyes for volume verification, ensuring sufficient and consistent sample collection by users in home-testing or field environments. Other innovations include multi-zone collection areas for different sample types, integrated barcoding for traceability, and tamper-evident packaging that meets regulatory compliance for forensic and clinical use. Dried blood spot cards, the most widely used format, are increasingly optimized for downstream applications such as PCR, mass spectrometry, ELISA, and next-generation sequencing (NGS), thereby aligning with high-sensitivity diagnostic workflows. Automation-compatible formats are also being developed to streamline laboratory processing. These product-level improvements are making specimen collection cards more versatile, user-friendly, and compatible with global diagnostic supply chains - key factors in enabling broader adoption in both high-throughput laboratories and point-of-care environments.Where Is Demand Rising Fastest, and Which Use Cases Are Leading Growth?
Demand for specimen collection cards is rising rapidly across clinical, research, and public health sectors, with particularly strong growth in applications such as newborn screening, infectious disease diagnostics, and genetic testing. Newborn screening programs remain the largest and most established user of dried blood spot cards, especially in North America, Europe, and parts of Asia-Pacific, where testing for metabolic and genetic disorders is routine. The global expansion of early detection programs for HIV, hepatitis, and tuberculosis is also driving card usage in developing countries, where conventional phlebotomy and refrigerated sample transport may be limited. Direct-to-consumer (DTC) genetic testing companies are increasingly incorporating at-home collection cards into their kits, allowing customers to submit saliva or cheek swab samples for ancestry, carrier screening, or wellness reports. Biobanks and longitudinal cohort studies are using specimen cards to collect, store, and archive samples from large populations in a compact, cost-effective manner. Emerging areas like pharmacogenomics, forensic toxicology, and therapeutic drug monitoring are also adopting these tools for non-invasive, scalable sampling. Governments, NGOs, and academic researchers are collectively contributing to demand, particularly in the wake of global health crises where mass sampling and surveillance are needed quickly and efficiently.What's Driving the Long-term Growth of the Specimen Collection Cards Market?
The growth in the specimen collection cards market is driven by several interlinked factors tied to global health priorities, diagnostic decentralization, technological innovation, and regulatory evolution. A primary driver is the rising need for scalable, cost-effective sample collection tools that support early diagnosis, outbreak tracking, and personalized treatment - especially in low-resource or geographically dispersed populations. The shift toward home-based healthcare, remote patient monitoring, and digital diagnostics is further expanding the relevance of specimen cards as foundational tools for sample acquisition outside traditional healthcare settings. Increased investment in genetic testing, clinical research, and bio-banking is creating long-term demand for cards that can store samples with high analyte integrity and compatibility with downstream molecular workflows. In parallel, public health agencies are integrating specimen cards into epidemiological studies and vaccination monitoring, reinforcing their role in population health management. Regulatory recognition of dried blood spot and alternative specimen cards as valid sources for clinical-grade data is also helping to normalize their use in diagnostics. As global focus intensifies on health equity, disease prevention, and rapid response capabilities, specimen collection cards are set to remain a vital enabler - bridging the gap between patients and laboratories, wherever they are in the world.Scope of Study:
The report analyzes the Specimen Collection Cards market in terms of units by the following Segments, and Geographic Regions/Countries:- Segments: Specimen (Blood, Saliva, Urine, Buccal Cells, Others); Material (Cotton & Cellulose-based, Fiber-based, Others); Application (New Born Screening, Infectious Diseases Testing, Therapeutic Drug Monitoring, Forensics, Research, Wellbeing / Health Monitoring, Other Applications)
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Blood segment, which is expected to reach US$221.1 Million by 2030 with a CAGR of a 3.7%. The Saliva segment is also set to grow at 2.9% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $122.8 Million in 2024, and China, forecasted to grow at an impressive 6.8% CAGR to reach $112.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Specimen Collection Cards Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Specimen Collection Cards Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Specimen Collection Cards Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Ahlstrom-Munksjö, ARCHIMEDlife, Becton, Dickinson and Company (BD), Capitainer AB, Cardinal Health and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 41 companies featured in this Specimen Collection Cards market report include:
- Ahlstrom-Munksjö
- ARCHIMEDlife
- Becton, Dickinson and Company (BD)
- Capitainer AB
- Cardinal Health
- CENTOGENE N.V.
- DBS System SA
- Eastern Business Forms, Inc. (EBF)
- EUROIMMUN AG
- F. Hoffmann-La Roche Ltd
- GenTegra LLC
- Greiner Bio-One International GmbH
- Hemaxis
- Lipomic Healthcare
- Medline Industries, LP
- Mitra Microsampling Devices (Neoteryx)
- Munktell Filter AB
- Neoteryx LLC
- PerkinElmer, Inc.
- Phenomenex, Inc.
- QIAGEN N.V.
- RDA Spot
- SARSTEDT AG & Co. KG
- Shimadzu Scientific Instruments
- Sirchie Acquisition Company, LLC
- Synergy Medical Systems LLP
- Thomas Scientific
- VWR International, LLC
- Whatman (part of Cytiva)
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ahlstrom-Munksjö
- ARCHIMEDlife
- Becton, Dickinson and Company (BD)
- Capitainer AB
- Cardinal Health
- CENTOGENE N.V.
- DBS System SA
- Eastern Business Forms, Inc. (EBF)
- EUROIMMUN AG
- F. Hoffmann-La Roche Ltd
- GenTegra LLC
- Greiner Bio-One International GmbH
- Hemaxis
- Lipomic Healthcare
- Medline Industries, LP
- Mitra Microsampling Devices (Neoteryx)
- Munktell Filter AB
- Neoteryx LLC
- PerkinElmer, Inc.
- Phenomenex, Inc.
- QIAGEN N.V.
- RDA Spot
- SARSTEDT AG & Co. KG
- Shimadzu Scientific Instruments
- Sirchie Acquisition Company, LLC
- Synergy Medical Systems LLP
- Thomas Scientific
- VWR International, LLC
- Whatman (part of Cytiva)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 71 |
| Published | June 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 450.8 Million |
| Forecasted Market Value ( USD | $ 559.7 Million |
| Compound Annual Growth Rate | 3.7% |
| Regions Covered | Global |
